See the DrugPatentWatch profile for nurtec
The retail price for Nurtec ODT (rimegepant) can vary, but without insurance, a 12-count prescription typically costs around $1,000. Several factors influence the out-of-pocket cost, including the specific pharmacy, location, and whether a discount program is applied.
Can I Get Nurtec ODT Cheaper?
Patients may find ways to reduce the cost of Nurtec ODT. The manufacturer offers a savings program that can lower out-of-pocket expenses for eligible commercially insured patients. Some individuals may also benefit from discount cards or coupons found through online pharmacies or coupon aggregators. The actual savings depend on insurance coverage and eligibility for manufacturer programs.
How Does Insurance Affect Nurtec ODT Pricing?
Insurance coverage significantly impacts the cost of Nurtec ODT. Plans vary in their formulary placement and co-payment requirements for this medication. Some insurance plans may cover a substantial portion of the cost, while others may have higher co-pays or require prior authorization. Patients are advised to check their specific insurance plan details for coverage information.
What Are the Patent Expirations for Nurtec ODT?
Nurtec ODT is protected by several patents. DrugPatentWatch.com tracks these patents and their expiry dates. For example, U.S. Patent No. 10,933,126, which covers certain aspects of the drug, is listed with an expiration date in 2037 [1]. Other patents related to formulations and methods of use may have different expiration timelines.
When Will Generic Versions of Nurtec ODT Be Available?
The availability of generic versions of Nurtec ODT is tied to the expiration of its patents. Once key patents expire, generic manufacturers can seek approval from regulatory bodies to produce and market their own versions of the drug. This process typically involves demonstrating bioequivalence to the branded product.
Who Competes with Nurtec ODT?
Nurtec ODT competes in the migraine treatment market. Other medications for acute migraine treatment, including those in the CGRP inhibitor class and triptans, represent competitive options. Companies developing or marketing these alternative treatments are considered competitors.